{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:35:26Z","timestamp":1787020526756,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","award":["PO20\/00538"],"award-info":[{"award-number":["PO20\/00538"]}],"id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05580-7","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:40:39Z","timestamp":1760085639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health system challenges and facilitators associated with adaptive cycling deployment of multiple first-line treatment for uncomplicated malaria: a pilot study in a malaria-endemic region of Kenya"],"prefix":"10.1186","volume":"24","author":[{"given":"Andrew","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Chege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Githuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Muga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Aspinall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Kokwaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"5580_CR1","unstructured":"WHO. World malaria report 2023. Geneva, World Health Organization. 2023. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023. Accessed 1 Mar 2024."},{"key":"5580_CR2","unstructured":"WHO. World Malaria Report 2020. Geneva, World Health Organization. 2020. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2020. Accessed 14 Jul 2025."},{"key":"5580_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12936-017-1942-5","volume":"16","author":"AP Phyo","year":"2017","unstructured":"Phyo AP, von Seidlein L. Challenges to replace ACT as first-line drug. Malar J. 2017;16:296.","journal-title":"Malar J"},{"key":"5580_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19:952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"5580_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s42003-022-03215-0","volume":"5","author":"L Zhu","year":"2022","unstructured":"Zhu L, van der Pluijm RW, Kucharski M, Nayak S, Tripathi J, White NJ, et al. Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Commun Biol. 2022;5:274.","journal-title":"Commun Biol"},{"key":"5580_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","volume":"395","author":"RW van der Pluijm","year":"2020","unstructured":"van der Pluijm RW, Tripura R, Hoglund RM, Pyae Phyo A, Lek D, ul Islam A, et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet. 2020;395:1345\u201360.","journal-title":"Lancet"},{"key":"5580_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00142-0","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021. https:\/\/doi.org\/10.1016\/S1473-3099(21)00142-0.","journal-title":"Lancet Infect Dis"},{"key":"5580_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"5580_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"37","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;37:411\u201323.","journal-title":"N Engl J Med"},{"key":"5580_CR10","unstructured":"WHO. World malaria report 2022. Geneva, World Health Organization, 2022. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2022. Accessed 25 Aug 2025."},{"key":"5580_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/1475-2875-13-452","volume":"13","author":"Y Lubell","year":"2014","unstructured":"Lubell Y, Dondorp A, Gu\u00e9rin PJ, Drake T, Meek S, Ashley E, et al. Artemisinin resistance\u2014modelling the potential human and economic costs. Malar J. 2014;13:452.","journal-title":"Malar J"},{"key":"5580_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/tropicalmed4010026","volume":"4","author":"C Nsanzabana","year":"2019","unstructured":"Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.","journal-title":"Trop Med Infect Dis"},{"key":"5580_CR13","volume-title":"Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019)","author":"WHO","year":"2020","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019). 1st ed. Geneva: World Health Organization; 2020.","edition":"1"},{"key":"5580_CR14","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.0804628105","volume":"105","author":"MF Boni","year":"2008","unstructured":"Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci USA. 2008;105:14216\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5580_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001984","volume":"13","author":"MF Boni","year":"2016","unstructured":"Boni MF, White NJ, Baird JK. The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies. PLoS Med. 2016;13:e1001984.","journal-title":"PLoS Med"},{"key":"5580_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pt.2020.09.011","volume":"37","author":"RW van der Pluijm","year":"2021","unstructured":"van der Pluijm RW, Amaratunga C, Dhorda M, Dondorp AM. Triple artemisinin-based combination therapies for malaria\u2014a new paradigm? Trends Parasitol. 2021;37:15\u201324.","journal-title":"Trends Parasitol"},{"key":"5580_CR17","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/cid\/cis958","volume":"56","author":"D Das","year":"2013","unstructured":"Das D, Tripura R, Phyo AP, Lwin KM, Tarning J, Lee SJ, et al. Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis. 2013;56:e48-58.","journal-title":"Clin Infect Dis"},{"key":"5580_CR18","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1038\/s41591-023-02551-w","volume":"29","author":"RJ Zupko","year":"2023","unstructured":"Zupko RJ, Nguyen TD, Ngabonziza JCS, Kabera M, Li H, Tran TNA, et al. Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda. Nat Med. 2023;29:2775\u201384.","journal-title":"Nat Med"},{"key":"5580_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14787210.2021.1962291","volume":"20","author":"C Rasmussen","year":"2022","unstructured":"Rasmussen C, Alonso P, Ringwald P. Current and emerging strategies to combat antimalarial resistance. Expert Rev Anti Infect Ther. 2022;20:353\u201372.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5580_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002132","volume":"3","author":"R Bate","year":"2008","unstructured":"Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa\u2014a six country study. PLoS ONE. 2008;3:e2132.","journal-title":"PLoS ONE"},{"key":"5580_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.seps.2013.04.001","volume":"47","author":"E Spiliotopoulou","year":"2013","unstructured":"Spiliotopoulou E, Boni MF, Yadav P. Impact of treatment heterogeneity on drug resistance and supply chain costs. Socioecon Plann Sci. 2013;47:158\u201371.","journal-title":"Socioecon Plann Sci"},{"key":"5580_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/1475-2875-11-422","volume":"11","author":"T Antao","year":"2012","unstructured":"Antao T, Hastings I. Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach. Malar J. 2012;11:422.","journal-title":"Malar J"},{"key":"5580_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/tropicalmed8040195","volume":"8","author":"JMT Kabor\u00e9","year":"2023","unstructured":"Kabor\u00e9 JMT, Siribi\u00e9 M, Hien D, Soulama I, Barry N, Baguiya A, et al. Feasibility and acceptability of a strategy deploying multiple first-line artemisinin-based combination therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso. Trop Med Infect Dis. 2023;8:195.","journal-title":"Trop Med Infect Dis"},{"key":"5580_CR24","doi-asserted-by":"publisher","first-page":"1041896","DOI":"10.3389\/fepid.2022.1041896","volume":"2","author":"MF Boni","year":"2022","unstructured":"Boni MF. Breaking the cycle of malaria treatment failure. Front Epidemiol. 2022;2:1041896.","journal-title":"Front Epidemiol"},{"key":"5580_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/bmj.320.7227.114","volume":"320","author":"C Pope","year":"2000","unstructured":"Pope C. Qualitative research in health care: analysing qualitative data. BMJ. 2000;320:114\u20136.","journal-title":"BMJ"},{"key":"5580_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5539\/gjhs.v8n1p165","volume":"8","author":"M Javid","year":"2015","unstructured":"Javid M, Hadian M, Ghaderi H, Ghaffari S, Salehi M. Application of the activity-based costing method for unit-cost calculation in a hospital. Glob J Health Sci. 2015;8:165.","journal-title":"Glob J Health Sci"},{"key":"5580_CR27","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/1468-0009.12301","volume":"95","author":"J Veillard","year":"2017","unstructured":"Veillard J, Cowling K, Bitton A, Ratcliffe H, Kimball M, Barkley S, et al. Better measurement for performance improvement in low- and middle-income countries: the primary health care performance initiative (PHCPI) experience of conceptual framework development and indicator selection: the primary health care performance initiative. Milbank Q. 2017;95:836\u201383.","journal-title":"Milbank Q"},{"key":"5580_CR28","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/tmi.13651","volume":"26","author":"B Dawkins","year":"2021","unstructured":"Dawkins B, Renwick C, Ensor T, Shinkins B, Jayne D, Meads D. What factors affect patients\u2019 ability to access healthcare? An overview of systematic reviews. Trop Med Int Health. 2021;26:1177\u201388.","journal-title":"Trop Med Int Health"},{"key":"5580_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163137","volume":"11","author":"EJ Dorado","year":"2016","unstructured":"Dorado EJ, Okoth SA, Montenegro LM, Diaz G, Barnwell JW, Udhayakumar V, et al. Genetic characterisation of Plasmodium falciparum isolates with deletion of the pfhrp2 and\/or pfhrp3 genes in Colombia: the Amazon Region, a challenge for malaria diagnosis and control. PLoS ONE. 2016;11:e0163137.","journal-title":"PLoS ONE"},{"key":"5580_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126805","volume":"10","author":"S Akinyi Okoth","year":"2015","unstructured":"Akinyi Okoth S, Abdallah JF, Ceron N, Adhin MR, Chandrabose J, Krishnalall K, et al. Variation in Plasmodium falciparum histidine-rich protein 2 (Pfhrp2) and Plasmodium falciparum histidine-rich protein 3 (Pfhrp3) gene deletions in Guyana and Suriname. PLoS ONE. 2015;10:e0126805.","journal-title":"PLoS ONE"},{"key":"5580_CR31","doi-asserted-by":"publisher","first-page":"14718","DOI":"10.1038\/s41598-017-15031-2","volume":"7","author":"KB Beshir","year":"2017","unstructured":"Beshir KB, Sep\u00falveda N, Bharmal J, Robinson A, Mwanguzi J, Busula AO, et al. Plasmodium falciparum parasites with histidine-rich protein 2 (pfhrp2) and pfhrp3 gene deletions in two endemic regions of Kenya. Sci Rep. 2017;7:14718.","journal-title":"Sci Rep"},{"key":"5580_CR32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12936-020-03362-x","volume":"19","author":"BB Agaba","year":"2020","unstructured":"Agaba BB, Anderson K, Gresty K, Prosser C, Smith D, Nankabirwa JI, et al. Molecular surveillance reveals the presence of pfhrp2 and pfhrp3 gene deletions in Plasmodium falciparum parasite populations in Uganda, 2017\u20132019. Malar J. 2020;19:300.","journal-title":"Malar J"},{"key":"5580_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3201\/eid2403.171723","volume":"24","author":"A Berhane","year":"2018","unstructured":"Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, et al. Major threat to malaria control programs by Plasmodium falciparum lacking histidine-rich protein 2. Eritrea Emerg Infect Dis. 2018;24:462\u201370.","journal-title":"Eritrea Emerg Infect Dis"},{"key":"5580_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12936-017-1768-1","volume":"16","author":"CT Kozycki","year":"2017","unstructured":"Kozycki CT, Umulisa N, Rulisa S, Mwikarago EI, Musabyimana JP, Habimana JP, et al. False-negative malaria rapid diagnostic tests in Rwanda: impact of Plasmodium falciparum isolates lacking hrp2 and declining malaria transmission. Malar J. 2017;16:123.","journal-title":"Malar J"},{"key":"5580_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1475-2875-12-34","volume":"12","author":"N Wurtz","year":"2013","unstructured":"Wurtz N, Fall B, Bui K, Pascual A, Fall M, Camara C, et al. Pfhrp2 and pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests. Malar J. 2013;12:34.","journal-title":"Malar J"},{"key":"5580_CR36","first-page":"36","volume":"216","author":"JB Parr","year":"2017","unstructured":"Parr JB, Verity R, Doctor SM, Janko M, Carey-Ewend K, Turman BJ, et al. Pfhrp2 -deleted Plasmodium falciparum parasites in the Democratic Republic of Congo: a national cross-sectional survey. J Infect Dis. 2017;216:36\u201344.","journal-title":"J Infect Dis"},{"key":"5580_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s41669-017-0021-8","volume":"1","author":"CC Ezenduka","year":"2017","unstructured":"Ezenduka CC, Falleiros DR, Godman BB. Evaluating the treatment costs for uncomplicated malaria at a public healthcare facility in Nigeria and the implications. PharmacoEconomics Open. 2017;1:185\u201394.","journal-title":"PharmacoEconomics Open"},{"key":"5580_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1475-2875-10-159","volume":"10","author":"P Chanda","year":"2011","unstructured":"Chanda P, Hamainza B, Moonga HB, Chalwe V, Banda P, Pagnoni F. Relative costs and effectiveness of treating uncomplicated malaria in two rural districts in Zambia: implications for nationwide scale-up of home-based management. Malar J. 2011;10:159.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05580-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05580-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05580-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T12:37:59Z","timestamp":1760359079000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05580-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5580"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05580-7","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all individual participants included in the study. For participants under 18\u00a0years of age, written informed consent was obtained from parents or legal guardians. All participants were informed of the study objectives, procedures, potential risks and benefits, and their right not to participate in the study without any effect on their care. The consent process was conducted in the English, Kiswahili, and Dholuo languages as preferred by the participants and all questions were answered before participation commenced.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"328"}}